Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the ...

Aperture Therapeutics, a biotechnology company pioneering next-generation precision medicines for neurodegenerative diseases, today announced the advancement of its matrix metalloproteinase-9 (MMP9) ...

New York, USA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain | ...

OSAKA, Japan--(BUSINESS WIRE)--In response to the rapid market expansion of oligonucleotide therapeutics that have potential to treat both common and intractable diseases, Nitto Denko Corporation ...

The use of oligonucleotides as therapeutic agents is of great interest, particularly when it comes to siRNA and antisense oligonucleotides. However, the difficulty of targeting the right organ and ...

When the drug fomivirsen was approved by the FDA in 1998 for the treatment of cytomegalovirus retinitis in patients with HIV/AIDs, it was hailed as a milestone in drug discovery because it was the ...

The 4-year deal is a big one for GSK, which has three oligo drug candidates in Phase 2 studies for hepatitis B. It’s even bigger for Wave. And it’s just one of several recent pacts highlighting the ...

Oligonucleotide therapeutics make up a small but rapidly growing segment of the overall global drug pipeline, with 245 programs currently in development today. While only one approved oligo ...

Please provide your email address to receive an email when new articles are posted on . Wave Life Sciences has announced positive results from its phase 1b/2a clinical trial of WVE-003, a potential ...